Patent intelligence · US
US 9550994
RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
Patent details — US 9550994
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 24, 2017
- Expiration
- Jan 19, 2037
- Applicant
- Arrowhead Pharmaceuticals, Inc.
- Claims
- 8
- CPC classes
- A61K, A61K31/7088, A61K31/713, A61K38/00
Quick answer
US 9550994 (RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma) is held by Arrowhead Pharmaceuticals, Inc.. Status: granted. Granted Jan 24, 2017. Expires Jan 19, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Arrowhead Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K31/7088, A61K31/713, A61K38/00, A61K48/00, A61K9/0048
More from Arrowhead Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12378558
RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use
granted -
US 12365897
RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use
granted -
US 12365899
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
granted -
US 12221610
RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use
granted -
US 12188017
Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin
granted -
US 12173086
Alpha-v beta-6 integrin ligands and uses thereof
granted -
US 12116573
Targeting ligands for therapeutic compounds
granted -
US 12110492
RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use
granted
Frequently asked questions
What is US patent 9550994?
US 9550994 (RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma) is held by Arrowhead Pharmaceuticals, Inc.. Status: granted. Granted Jan 24, 2017. Expires Jan 19, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9550994?
Arrowhead Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 126 pharmaceutical patents for this assignee.
When does US 9550994 expire?
Our index shows an expiration date of Jan 19, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.